Bicalutamide

Spécifications

90357-06-5Numéro CAS

618-534-3Numéro CE

N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamideNom IUPAC

C18H14F4N2O4SFormule chimique

430.4 g/molMasse molaire

bicalutamide; 90357-06-5; Casodex; Calutide; Kalumid; ICI 176334; ICI-176334; bicalutamida; N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide; DTXSID2022678; ICI 176,334; A0Z3NAU9DP; NSC-759816; Cosudex; ICI176,334-1; DTXCID00209197; NSC722665; Propanamide, N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methyl-, (+-)-; N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorobenzenesulfonyl)-2-hydroxy-2-methylpropanamide; bicalutamidum; N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-fluorobenzenesulfonyl)-2-hydroxy-2-methylpropanamide; N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamide; RefChem:54538; 4'-cyano-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide; CHEBI:3090; L02BB03; 4-cyano-3-trifluoromethyl-N-(3-p-fluorophenylsulfonyl-2-hydroxy-2-methylpropionyl)aniline; 4'-Cyano-alpha,alpha,alpha-trifuloro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide; (+-)-N-(4-Cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methylpropanamide; N-(4-Cyano-3-(trifluoromethyl)phenyl)3-3((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methyl-propanamide; N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methylpropanamide; Bicalutamide (CDX); MFCD00869971; C18H14F4N2O4S; Propanamide, N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-; CHEMBL409; N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide; Bicalutamide Crystalline Form II; Raffolutil; SMR000466329; Casodex (TN); CAS-90357-06-5; SR-01000759410; UNII-A0Z3NAU9DP; BRN 5364666; Propanamide,; CCRIS 8728; Calutide;; Casodex;; Cosudex;; Bicalutamide CRS; HSDB 7655; NCGC00167487-01; Bicalutamide [USAN:USP:INN:BAN]; (+-)-4'-Cyano-alpha,alpha,alpha-trifluoro-3-((p-fluorophenyl)sulfonyl)-2-methyl-m-lactotoluidide; KS-1161; Bicalutamide (Casodex); CPD000466329; Bicalutamide (Standard); BICALUTAMIDE [MI]; BICALUTAMIDE [INN]; BICALUTAMIDE [JAN]; BICALUTAMIDE [HSDB]; BICALUTAMIDE [USAN]; BicalutamideICI-176334; SCHEMBL3611; BICALUTAMIDE [VANDF]; BICALUTAMIDE [MART.]; MLS000759437; MLS001424047; BICALUTAMIDE [USP-RS]; BICALUTAMIDE [WHO-DD]; GTPL2863; orb1310668; SCHEMBL29353850; BDBM18525; Bicalutamide (JP18/USP/INN); CHEBI:91617; EX-A962; CHEBI:144093; BICALUTAMIDE [ORANGE BOOK]; GLXC-06685; HMS2051B13; HMS2089N12; HMS2232H03; HMS3263M13; HMS3372K05; HMS3393B13; HMS3654K18; HMS3714P13; HMS5079I13; Pharmakon1600-01504827; BICALUTAMIDE [EP MONOGRAPH]; BICALUTAMIDE [USP IMPURITY]; MSK11156; SYB76979; BICALUTAMIDE [USP MONOGRAPH]; Tox21_112488; Tox21_303560; Tox21_501026; EBC-00668; HY-14249R; NSC759816; s1190; AKOS015895073; AC-4232; Bicalutamide for system suitability CRS; CCG-100951; CCG-220876; CCG-222330; CS-1296; DB01128; IC58278; LP01026; NC00201; NSC 759816; NSC-722665; SB17301; SDCCGSBI-0633779.P001; NCGC00167977-01; NCGC00167977-02; NCGC00167977-03; NCGC00167977-09; NCGC00167977-20; NCGC00257459-01; NCGC00261711-01; HY-14249; N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methyl-propanamide; SY057461; DB-041165; B3206; NS00000400; SW197581-4; T0380; Bicalutamide (CDX), >=98% (HPLC), powder; C08160; D00961; AB00639963-06; AB00639963-08; AB00639963-09; AB00639963_10; EN300-1715981; F048360; Q1988832; SR-01000759410-4; SR-01000759410-5; BRD-A29485665-001-03-7; BRD-A29485665-001-11-0; BRD-A29485665-001-12-8; Z2108698963; Bicalutamide, British Pharmacopoeia (BP) Reference Standard; Bicalutamide, European Pharmacopoeia (EP) Reference Standard; Bicalutamide, United States Pharmacopeia (USP) Reference Standard; 4'-cyano-3-[(4- fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-3'-trifluoromethylpropionanilide; 4'-cyano-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-3'-trifluoromethylpropionanilide; Bicalutamide for system suitability, European Pharmacopoeia (EP) Reference Standard; Bicalutamide, Pharmaceutical Secondary Standard; Certified Reference Material; (+/-)-4'-CYANO-.ALPHA.,.ALPHA.,.ALPHA.-TRIFLUORO-3-((P-FLUOROPHENYL)SULFONYL)-2-METHYL-M-LACTOTOLUIDIDE; (2R)-N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methylpropanamidenone; N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methylpropanamide; N-[(4-CYANO-3-TRIFLUOROMETHYL)PHENYL]-3-[(4-FLUOROPHENYL)SULFONYL]-2-HYDROXY-2-METHYLPROPANAMIDE; N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorobenzene-1-sulfonyl)-2-hydroxy-2-methylpropanamide; N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorobenzene)sulfonyl]-2-hydroxy-2-methylpropanamide; N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropionamide; N-[4-cyano-3-trifluoromethyl-phenyl]-3-[4-fluorophenyl-sulfonyl]-2-hydroxy-2-methyl-propionamide; PROPANAMIDE, N-(4-CYANO-3-(TRIFLUOROMETHYL)PHENYL)-3-((4-FLUOROPHENYL)SULFONYL)-2-HYDROXY-2-METHYL-, (+/-)-; Bicalutamide micronizedSynonymes